AR and prostate carcinoma: The activity of tasquinimod against human prostate cancer was evaluated using xenografts in intact male nude mice chosen to encompass the range of phenotypes and genotypes typical of clinical tumours in patients: localised and metastatic, androgen receptor (AR)-positive and AR-negative, AR wild type and mutant, and PSA-positive and PSA-negative cancers.